Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
A clinical study to evaluate the efficacy, safety and tolerability of two dose ranges of
risperidone (1 to 3 mg/day, and 4 to 6 mg/day) versus placebo (an inactive substance like a
sugar pill) in adolescents (aged 13 to 17 years) with schizophrenia (i.e. abnormal behavior
and thoughts). The study duration is about 6 to 7 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.